Evidence map›Paper›PMID 42137280›Full record

ArticleMolecular therapy. Advances2026

Immune shielding of viral vectors via capsid engineering with genetically encoded zwitterionic peptides.

Shao-Chia Lu, Olivia X Ma, Alex A Anwar, Dimitrije Ratkov, Janarjan Bhandari, Daniel J Montiel-Garcia, Michael J Hansen, Mary E Barry, Vijay S Reddy, Michael A Barry

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shao-Chia LuDivision of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Olivia X MaThe Hormel Institute, University of Minnesota, Austin, MN 55912, USA.
Alex A AnwarDivision of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Dimitrije RatkovVirology and Gene Therapy Track, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN 55905, USA.
Janarjan BhandariThe Hormel Institute, University of Minnesota, Austin, MN 55912, USA.
Daniel J Montiel-GarciaDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Michael J HansenDepartment of Immunology, Mayo Clinic, Rochester, MN 55905, USA.
Mary E BarryDivision of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Vijay S ReddyThe Hormel Institute, University of Minnesota, Austin, MN 55912, USA.
Michael A BarryDepartment of Immunology, Mayo Clinic, Rochester, MN 55905, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pre-existing neutralizing antibodies (NAbs) and blood proteins can rapidly inactivate therapeutic viral vectors and trigger immune toxicities in patients. To overcome these challenges, we engineered the surfaces of adenovirus (Ad) by incorporating genetically encoded "protective shields" to reduce the recognition by host factors. AlphaFold3 modeling showed that inserting a structured biotin acceptor peptide (BAP) into hypervariable region 5 (HVR5) of the viral capsid protein hexon produced a rigid surface protrusion, whereas inserting a disordered, zwitterionic glutamic acid-lysine (EK) peptide formed a flexible canopy over the hexon. Although inserting EK peptides into the capsid impaired viral entry and intracellular trafficking that led to reduced viral transduction

Indexed as

adenovirusesblood factorscapsid engineeringcryo-EMgenetically encodableimmune stealthneutralizing antibodiesviral vectorszwitterionic peptides

Identifiers

PMID42137280
PMCPMC13148926

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.